Peritumoral lymphatic invasion is associated with regional lymph node metastases in prostate adenocarcinoma

Modern Pathology

Volumn 19, Issue 3, 2006, Pages 392-398

  Roma, Andres A ^a   Magi Galluzzi, Cristina ^a   Kral, Melinda A ^a   Jin, Tao T ^a   Klein, Eric A ^a   Zhou, Ming ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Lymph node metastases; Lymphangiogenesis; Lymphatic vessels; Prostate adenocarcinoma

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; EVALUATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH VESSEL; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA;

ADENOCARCINOMA; AGED; ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; SIALOGLYCOPROTEINS;

EID: 33244490973     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800546     Document Type: Article

References (29)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001;7:462-468.
3. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573-583.
4. Stacker SA, Baldwin ME, Achen MG. The role o tumor lymphangiogenesis in metastatic spread. FASEB J 2002;16:922-934.
5. Baldwin ME, Stacker SA, Achen MG. Molecular controls of lymphangiogenesis. Bio Essays 2002;24:1030-1040.
6. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98:413-423.
7. Schoppmann SF, Bayer G, Aumayr K, et al. Austrian Breast and Colorectal Cancer Study Group. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306-312.
8. Franchi A, Gallo O, Massi D, et al. Tumor lymphangiogenesis in head and neck squamous call carcinoma. A morphometric study with clinical correlations. Cancer 2004;101:973-978.
9. Hashimoto I, Kodama J, Seki N, et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer 2001;85:93-97.
10. Rubbia-Brandt L, Terris B, Giostra E, et al. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin Cancer Res 2004;10:6919-6928.
11. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951-1960.
12. Williams CSM, Leek DR, Robson MA, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003;200:137-274.
13. Vleugel MM, Bos R, van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 2004;57:746-751.
14. McDavid K, Lee J, Fulton JP, et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-186.
15. Bono AV. The global state of prostate cancer: epidemiology and screening in the second millennium. BJU Int 2004;94(Suppl 3):1-2.
16. Walsh P. Campbell's Urology, 8th edn. Saunders: London, 2002.
17. Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999;80:309-313.
18. Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004;10:5137-5144.
19. Li R, Younes M, Wheeler TM, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004;58:193-199.
20. Jennbacken K, Vallbo C, Wang W, et al. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005;65:110-116.
21. Trojan L, Michel MS, Rensch F, et al. Lymph and blood vessel architecture in benign and malignant prostatic tissue: Lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). J Urol 2004;172:103-107.
22. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
23. Fogt F, Zimmerman RL, Ross HM, et al. Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2-40. Oncol Rep 2004;11:47-50.
24. Furusato M, Mostofi FK. Intraprostatic lymphatics in man: light and ultrastructural observations. Prostate 1980;1:15-23.
25. Leu AJ, Berk DA, Lymboussaki A, et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000;60:4324-4327.
26. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-1886.
27. Ohori M, Scardino PT, Lapin SL, et al. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 1993;17:1252-1261.
28. Graham Jr SD, Napalkov P, Watts L, et al. Microvascular invasion of the seminal vesicles in adenocarcinoma of the prostate. Prostate 1996;28:359-363.
29. Renshaw AA, Chang H, D'Amico AV. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol 1997;107:704-708.